These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 17917474

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Anticipatory nausea: the role of individual differences related to sensory perception and autonomic reactivity.
    Zachariae R, Paulsen K, Mehlsen M, Jensen AB, Johansson A, von der Maase H.
    Ann Behav Med; 2007 Feb; 33(1):69-79. PubMed ID: 17291172
    [Abstract] [Full Text] [Related]

  • 3. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
    Shih V, Wan HS, Chan A.
    Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
    [Abstract] [Full Text] [Related]

  • 4. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
    Wilcox PM, Fetting JH, Nettesheim KM, Abeloff MD.
    Cancer Treat Rep; 1982 Aug; 66(8):1601-4. PubMed ID: 7049385
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Results of a study on fatigue in breast cancer patients receiving adjuvant chemotherapy: the first four days after treatment are the worst].
    de Jong N, Kester AD, Schouten HC, Abu-Saad HH, Courtens AM.
    Pflege Z; 2007 Nov; 60(11):620-5. PubMed ID: 18062627
    [Abstract] [Full Text] [Related]

  • 8. Trait anxiety and anticipatory immune reactions in women receiving adjuvant chemotherapy for breast cancer.
    Fredrikson M, Fürst CJ, Lekander M, Rotstein S, Blomgren H.
    Brain Behav Immun; 1993 Mar; 7(1):79-90. PubMed ID: 8471800
    [Abstract] [Full Text] [Related]

  • 9. The effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancer.
    Williams SA, Schreier AM.
    Oncol Nurs Forum; 2004 Mar; 31(1):E16-23. PubMed ID: 14722602
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tastes associated with parenteral chemotherapy for breast cancer.
    Fetting JH, Wilcox PM, Sheidler VR, Enterline JP, Donehower RC, Grochow LB.
    Cancer Treat Rep; 1985 Nov; 69(11):1249-51. PubMed ID: 3841501
    [Abstract] [Full Text] [Related]

  • 12. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients.
    Molassiotis A, Yam BM, Yung H, Chan FY, Mok TS.
    Support Care Cancer; 2002 Mar; 10(2):139-45. PubMed ID: 11862503
    [Abstract] [Full Text] [Related]

  • 13. A comparison of patient-reported side effects among three chemotherapy regimens for breast cancer.
    Greene D, Nail LM, Fieler VK, Dudgeon D, Jones LS.
    Cancer Pract; 1994 Mar; 2(1):57-62. PubMed ID: 8055007
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer.
    Mohapatro SK, Dandapat MC, Padhi NC.
    J Indian Med Assoc; 1992 Feb; 90(2):39-42. PubMed ID: 1588118
    [Abstract] [Full Text] [Related]

  • 18. The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial.
    Molassiotis A, Yung HP, Yam BM, Chan FY, Mok TS.
    Support Care Cancer; 2002 Apr; 10(3):237-46. PubMed ID: 11904789
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y.
    J Clin Oncol; 2009 Mar 20; 27(9):1368-74. PubMed ID: 19204202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.